Evidence map›Paper›PMID 34987523›Full record

ReviewFrontiers in immunology2021

Platelet CLEC2-Podoplanin Axis as a Promising Target for Oral Cancer Treatment.

Byeong-Oh Hwang, Se-Young Park, Eunae Sandra Cho, Xianglan Zhang, Sun Kyoung Lee, Hyung-Joon Ahn, Kyung-Soo Chun, Won-Yoon Chung, Na-Young Song

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 5 pooled it
3.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 5 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Gut-derivedmSystems · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. TEP RNA: a new frontier for early diagnosis of NSCLC.Journal of cancer research and clinical oncology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Byeong-Oh HwangDepartment of Applied Life Science, The Graduate School, Yonsei University, Seoul, South Korea.
Se-Young ParkDepartment of Applied Life Science, The Graduate School, Yonsei University, Seoul, South Korea.
Eunae Sandra ChoBK21 Four Project, Yonsei University College of Dentistry, Seoul, South Korea.
Xianglan ZhangOral Cancer Research Institute, Yonsei University College of Dentistry, Seoul, South Korea.
Sun Kyoung LeeDepartment of Oral Biology, Yonsei University College of Dentistry, Seoul, South Korea.
Hyung-Joon AhnDepartment of Orofacial Pain and Oral Medicine, Dental Hospital, Yonsei University College of Dentistry, Seoul, South Korea.
Kyung-Soo ChunCollege of Pharmacy, Keimyung University, Daegu, South Korea.
Won-Yoon ChungDepartment of Applied Life Science, The Graduate School, Yonsei University, Seoul, South Korea.
Na-Young SongDepartment of Applied Life Science, The Graduate School, Yonsei University, Seoul, South Korea.
Yonsei University College of DentistryKeimyung University · KRYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer tissues are not just simple masses of malignant cells, but rather complex and heterogeneous collections of cellular and even non-cellular components, such as endothelial cells, stromal cells, immune cells, and collagens, referred to as tumor microenvironment (TME). These multiple players in the TME develop dynamic interactions with each other, which determines the characteristics of the tumor. Platelets are the smallest cells in the bloodstream and primarily regulate blood coagulation and hemostasis. Notably, cancer patients often show thrombocytosis, a status of an increased platelet number in the bloodstream, as well as the platelet infiltration into the tumor stroma, which contributes to cancer promotion and progression. Thus, platelets function as one of the important stromal components in the TME, emerging as a promising chemotherapeutic target. However, the use of traditional antiplatelet agents, such as aspirin, has limitations mainly due to increased bleeding complications. This requires to implement new strategies to target platelets for anti-cancer effects. In oral squamous cell carcinoma (OSCC) patients, both high platelet counts and low tumor-stromal ratio (high stroma) are strongly correlated with increased metastasis and poor prognosis. OSCC tends to invade adjacent tissues and bones and spread to the lymph nodes for distant metastasis, which is a huge hurdle for OSCC treatment in spite of relatively easy access for visual examination of precancerous lesions in the oral cavity. Therefore, locoregional control of the primary tumor is crucial for OSCC treatment. Similar to thrombocytosis, higher expression of podoplanin (PDPN) has been suggested as a predictive marker for higher frequency of lymph node metastasis of OSCC. Cumulative evidence supports that platelets can directly interact with PDPN-expressing cancer cells

Indexed as

AnimalsAntineoplastic AgentsBlood PlateletsCell MovementHumansLectins, C-TypeMembrane GlycoproteinsMolecular Targeted TherapyMouth NeoplasmsNeoplasm InvasivenessPlatelet Aggregation InhibitorsPodoplaninSignal TransductionSquamous Cell Carcinoma of Head and NeckTumor MicroenvironmentAntineoplastic AgentsLectins, C-TypeMembrane GlycoproteinsPDPN protein, humanPlatelet Aggregation InhibitorsPodoplaninCLEC2ezrin/radixin/moesin (ERM)oral cancerPDPNplateletstumor cell-induced platelet aggregation (TCIPA)

Identifiers

PMID34987523
PMCPMC8721674
OpenAlexW4200382593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.